MeiraGTx Holdings plc
NASDAQ:MGTX · NASDAQ Global Select
+$0.53 today
Vol 2.22M · Avg 0.84M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:MGTX · Revenue to Net Income
Key Ratios
Analysis
$79.8M of revenue converted into -$120.5M of net income for the selected period. Gross margin is -210.9% and net margin is -7289.4%, showing how much revenue survives after costs and taxes. EPS is $-1.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.4M +144.6% | $33.3M +137.4% | $14.0M -12.0% | $15.9M -57.8% | $37.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $4.8M -79.6% | $23.8M | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $76.5M +706.8% | $9.5M -32.3% | $14.0M -12.0% | $15.9M -57.8% | $37.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.0% +65.5pp | 28.5% -71.5pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $129.6M +8.5% | $119.5M +15.1% | $103.8M +21.1% | $85.7M +28.5% | $66.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $52.9M -2.4% | $54.2M +14.6% | $47.3M +1.6% | $46.5M +6.4% | $43.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $182.5M +5.1% | $173.7M +15.0% | $151.1M +14.2% | $132.3M +19.8% | $110.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $12.6M -1.7% | $12.8M -6.6% | $13.7M +59.6% | $8.6M +9.3% | $7.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$89.4M +26.5% | -$121.7M -113.3% | -$57.1M +50.8% | -$116.1M -62.6% | -$71.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -109.8% +255.8pp | -365.7% +41.4pp | -407.0% +322.0pp | -729.1% -539.7pp | -189.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$106.0M +35.5% | -$164.2M -19.8% | -$137.1M -17.8% | -$116.4M -59.9% | -$72.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -130.2% +363.2pp | -493.4% +484.4pp | -977.8% -246.9pp | -730.9% -537.9pp | -193.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.8M -56.1% | $4.1M +82.4% | $2.3M +192.4% | $777.0K +266.5% | $212.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $12.2M -8.1% | $13.3M +0.2% | $13.2M +167.8% | $4.9M +1617.4% | $288.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$8.2M -150.1% | $16.4M -69.0% | $53.0M +500.0% | -$13.3M -94.9% | -$6.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$114.2M +22.7% | -$147.8M -75.9% | -$84.0M +35.2% | -$129.6M -62.9% | -$79.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -140.3% +303.8pp | -444.1% +155.4pp | -599.5% +214.7pp | -814.2% -603.1pp | -211.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$114.2M +22.7% | -$147.8M -75.9% | -$84.0M +35.2% | -$129.6M -62.9% | -$79.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -140.3% +303.8pp | -444.1% +155.4pp | -599.5% +214.7pp | -814.2% -603.1pp | -211.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +33.0% | -$2 -42.3% | -$1 +48.1% | -$3 -59.4% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +33.0% | -$2 -42.3% | -$1 +48.1% | -$3 -59.4% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $80.4M +15.2% | $69.8M +23.6% | $56.5M +25.0% | $45.2M +2.4% | $44.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $80.4M +15.2% | $69.8M +23.6% | $56.5M +25.0% | $45.2M +2.4% | $44.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.33B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.47B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.43B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.40B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.38B
Absci Corporation
NASDAQ:ABSI
$1.13B
Replimune Group, Inc.
NASDAQ:REPL
$838.94M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$577.80M
Arvinas, Inc.
NASDAQ:ARVN
$487.14M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MGTX generate?
MeiraGTx Holdings plc (MGTX) reported $81.39M of revenue in fiscal 2025.
Is MGTX profitable?
MeiraGTx Holdings plc (MGTX) reported -$114,201,000.00 of net income, with a net margin of -140.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.